Skip to main content

Advertisement

Table 5 IPDASi (probabilities) and development process ratings for tools

From: A review of decision support, risk communication and patient information tools for thrombolytic treatment in acute stroke: lessons for tool developers

  IPDASi (Probabilities) items [12] Development process items
  1 n (%) 2 n (%) 3 n (%) 4 n (%) 5 n (%) 6 n (%) 7 n (%) 8 n (%) Median (IQR) probabilities total 1 n (%) 2 n (%) 3 n (%) 4 n (%) 5 n (%) 6 n (%)
RCT 5 (100) 5 (100) 5 (100) 2 (40) 2 (40) 1 (20) 4 (80) 5 (100) 5 (3) 3 (60) 1 (20) 0 (0) 1 (20) 1 (20) 0 (0)
PIT 17 (100) 17 (100) 13 (77) 6 (36) 2 (12) 1 (6) 6 (36) 3 (18) 4 (1.5) 8 (47) 1 (6) 0 (0) 2 (12) 3 (18) 0 (0)
BDA 2 (67) 2 (67) 0 (0) 2 (67) 2 (67) 1 (33) 1 (33) 0 (0) 4 (0) 3 (100) 1 (33) 0 (0) 0 (0) 0 (0) 0 (0)
SI 1 (100) 1 (100) 1 (100) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0) 4 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Overall 25 (96) 25 (96) 19 (73) 10 (39) 7 (27) 3 (12) 11 (42) 8 (31) 4 (2) 14 (54) 3 (12) 0 (0) 3 (12) 4 (15) 0 (0)
  1. RCT = Risk communication tool PIT = Patient information tool BDA = Brief decision aid SI = Standardised information.
  2. IPDASi (Probabilities) items: [12].
  3. 1 = provides information about outcome probabilities (OPs) associated with the options; 2 = specifies defined group (reference class) of patients for which the OPs apply; 3 = specifies the event rates for OPs (in natural frequencies); 4 = specifies time period over which the OPs apply; 5 = allows the user to compare OPs across options using the same denominator and time period; 6 = provides information about the levels of uncertainty around event/OPs; 7 = provides more than one way of viewing the probabilities; 8 = provides balanced information about event or OPs to limit framing biases.
  4. Development process items:
  5. 1 = evidence that developers have considered best available evidence; 2 = intervention based on an established theory/body of evidence; 3 = elicitation study on risk/benefit information required by patients/families or clinicians; 4 = tool subjected to ‘testing’ in patients and families or clinicians; 5 = development of tool guided by steering group; 5 = tool subjected to exploratory trial.